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Summary Abnormalities of the EGF receptor and/or the related ERBB2 receptor occur in a significant
proportion of cases of human breast cancer and are important influences in the behaviour of this tumour type.
In this report we demonstrate by nucleic acid analysis and immunohistochemistry that the recently recognised
third member of this gene family, ERBB3, shows a wide range of expression in breast cancer, and shows
stronger immunoreactivity than that observed in normal tissue in 43 out of 195 cases (22%) of primary breast
cancer. Overexpression of ERBB3 appears to result from increased levels of gene transcription since in none of
the cell lines or primary cancers analysed did we find evidence of gene amplification. High expression of
ERBB3 is positively associated with the presence of lymph node metastases, but there was no demonstratable
relationship with patient survival in this series.
A great deal of progress has been made in understanding the
oncogenes and growth factors which are involved in the
molecular pathogenesis of breast cancer, allowing the devel-
opment of new markers for patient selection and prognosis
and potentially the identification of new targets for therapy.
The type 1 family of receptor tyrosine kinases including the
epidermal growth factor receptor (EGFR) and the ERBB2
(or HER2) protein have been recognised as being particularly
important influences in breast cancer (Gullick 1990a). Both
of these receptor proteins are expressed at low levels on
normal breast epithelial and myoepithelial cells and are often
overexpressed in breast cancer. Patients with tumours in
which there is elevated EGFR expression have a relatively
poor prognosis with shorter relapse-free survival and overall
survival (Sainsbury et al., 1987; Costa et al., 1988). Overex-
pression of the ERBB2 protein is also a marker of poor
prognosis for node-positive disease (Slamon et al., 1987) and
probably also for node-negative disease (Perren, 1991). More
exciting, however, is the accumulating evidence that the
ERBB2 receptor protein has potential as a target for
antibody-directed therapy (Shepard et al., 1991) and other
approaches such as inhibition of receptor dimerisation and
tyrosine kinase function (Gullick 1990b).
A new member of the type 1 receptor family, ERBB3, was
cloned by two groups (Kraus et al., 1989; Plowman et al.,
1990) and found to be expressed at the RNA level in a
number of tumour cell lines, including 6 out of 17 breast
cancer cell lines (Plowman et al., 1990). Because amplification
and/or overexpression of the other members of this receptor
family (EGFR and ERBB2) are clearly important factors in
neoplastic transformation ofbreast epithelium, we were inter-
ested to determine whether ERBB3 was activated by similar
mechanisms. The aim of our present study was to investigate
the possibility that abnormalities of structure and/or expres-
sion of this receptor occur in human breast cancer. We have
therefore examined in detail a panel of breast cell lines (both
malignant and non-malignant) and a large series of tumour
samples well-characterised for clinicopathological parameters
and activation of oncogenes. We have used Southern and
Northern blot analysis with a specific ERBB3 probe to deter-
mine gene structure and mRNA expression and also
immunohistochemistry with two new antibodies raised
against ERBB3-specific peptides for protein expression (Pri-
gent et al., 1992). The data were analysed for any associa-
tions between ERBB3 expression and factors such as tumour
size, grade and stage, expression of oncogenes and patient
survival.
Materials and methods
Tumour and normal tissue samples
Immunohistochemical studies were carried out on formalin-
fixed, paraffin-embedded sections from 195 patients with
primary infiltrating breast cancer of various types managed
at Guy's Hospital, London. One hundred and sixty eight
patients had infiltrating ductal carcinoma, 24 had infiltrating
lobular carcinoma and in three patients carcinoma was of
special type. One hundred and forty two of the patients were
treated by modified radical mastectomy and 53 patients had
conservation treatment and radiotherapy. Twenty nine pa-
tients received adjuvant therapy: in eight it was endocrine
therapy and in 21 it was CMF chemotherapy (cyclophos-
phamide, methotrexate and 5-fluorouracil). The patients were
treated at Guy's Hospital between 1979 and 1982 and have a
medium follow-up of 10.04 years. Patients selected for this
study all had verified follow-up data and the presence and
date of recurrence was determined in a standard manner
according to the criteria of Hayward et al. (1978).
There was sufficient formalin-fixed, paraffin-embedded
material available for further immunohistochemical investiga-
tions. The overall survival of these patients is representative
of the survival of all patients with breast cancer managed at
Guy's Hospital during the same period. A large volume of
information is available for these patients including analysis
of expression of EGF receptors (immunohistochemistry with
antibody 12E, Gullick et al., 1991a), ERBB2 (immunohis-
tochemistry with antibody 21N, Venter et al., 1987), oes-
trogen receptors (as described by King et al., 1979) and p53
(immunohistochemistry with antibody CM1, Midgley et al.,
1992) together with clinical and pathological parameters.
High molecular weight DNA was prepared from 36 human
breast cancer samples which had been snap-frozen in liquid
nitrogen immediately after surgical resection and subse-
quently stored at - 70°C and also from normal peripheral
blood leucocytes of these patients. In a pilot study immuno-
histochemical staining with two antibodies (49.3 and 61.3, see
below) for ERBB3 protein was performed on paraffin sec-
tions of the breast tumours from these cases.
Thirty six biopsy samples of non-neoplastic breast tissue
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from women in different phases of the menstrual cycle were
also examined for immunoreactivity with antibodies to
ERBB3.
Cell lines
The MTSV-1.7, MRSV-2.1 and MRSV-2.4 immortalized,
non-malignant breast cell lines (Bartek et al., 1991) were
kindly donated by Dr Joyce Taylor-Papadimitrou, ICRF
London. All breast cancer cell lines were obtained from the
American Type Culture Collection. Cell pellets in agarose
plugs were fixed in formalin and embedded in paraffin
blocks.
The transfected cell line 293/HER3 (cotransfected with the
HER3x expression vector containing full-length ERBB3
cDNA in pCDM8 and the pMClneo plasmid) and the
parent line 293 were obtained from Dr Greg Plowman,
Bristol-Myers Squibb Pharmaceutical Research Institute, Se-
attle, USA. A431 vulval carcinoma cell line and SKBR3
breast carcinoma cell line were both obtained from Cell
Production, Imperial Cancer Research Fund, Lincoln's Inn
Fields.
Immunoblotting
This was performed (Figure 1) as previously described (Gul-
lick et al., 1986) on cell lysates.
Southern blot analysis
10jig DNA from each of the paired normal/tumour samples
was digested with restriction enzymes EcoRI or PstI, elec-
trophoresed through 0.8% agarose gel and blotted onto
nylon membranes (Hybond-N+, Amersham). Hybridisation
was performed with a cDNA probe for ERBB3 labelled with
32P-ATP by the random primer method, and filters washed at
high stringency in 0.1 x SSC/0.1% SDS at 65°C for 10 min.
The ERBB3 probe was generated by PCR from a placental
cDNA library and represents positions 3625 to 4138 of the
sequence reported by Kraus et al. (1989), including sequences
encoding the C-terminal 170 amino acids of the ERBB3
protein. The 513 base pair fragment was cloned in Bluescript
and double-stranded sequence analysis performed to confirm
that it conformed in every respect to the ERBB3 sequence
published by Kraus et al. (1989). It is completely specific for
ERBB3 in hybridisation analysis of human DNA and RNA.
After autoradiography the filters were stripped and rep-
robed with a probe for ,-actin (Cleveland et al., 1980).
RNA analysis
RNA was extracted from cultured cells and Northern blots
prepared by standard techniques (Ausubel et al., 1991). Blots
were hybridised with the ERBB3 cDNA probe as described
above.
Table I Expression of ERB3 messenger RNA in human breast cell
lines











BT483 + + +
MDA-MB453 + + +
T47D + + +
+/-, barely detectable on 5 days exposure; +, detectable on 5
days exposure; + +, detectable on 3 days exposure; + ++,
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Figure 1 Immunoblot of cell lysates probed with the 49.3
antiserum. A specific band is seen only in the track derived from
the ERBB3-transfected cells (HER3), while no signal is seen in
the tracks derived from the parent cells (293), EGFR-over-
expressing cells (A431) and ERBB2-expressing cells (SKBR3).
After autoradiography the filters were stripped and rep-
robed with for ,-actin.
Immunohistochemistry
The immunohistochemical staining of paraffin sections was
carried out using the affinity-purified rabbit polyclonal anti-
sera to peptide sequences of ERBB3 as previously described
(Prigent et al., 1992). The antibodies were shown to spec-
ifically recognise ERBB3 protein in 293 cells cotransfected
with the HER 3 x expression vector (full length ERBB3/
HER3 cDNA in pCDM8) and the pMClneo plasmid (Figure
1). All cases were immunostained with the antibody 49.3
while 36 cases (those examined at the DNA level by Southern
blot, see above) were examined both with antibody 49.3 and
another specific anti-ERBB3 antibody 61.3 (Prigent et al.,
1992). Briefly, the primary antibody (49.3 at a concentration
of 5jig ml-' or 61.3 at a concentration of 1 .tg ml-, in
phosphate-buffered saline (PBS) with 0.5% bovine serum
albumin) was incubated with the section for 1 h at room
temperature. The second layer was biotinylated anti-rabbit
antibody (Dako, Copenhagen, Denmark) employed at a dilu-
tion of 1/500 and incubated for 40mins. After washing in
PBS, the third layer comprising horseradish peroxidase-
conjugated ABC kit (Dako, Copenhagen, Denmark) was
applied for 30 min and after washing in PBS the complex
visualised with diaminobenzidine tetrahydrochloride solution
for 5 min. Sections were counterstained with Mayer's haema-
toxylin. Negative controls comprised serial sections incubated
with buffer alone instead of primary antibody, and blockade
of primary antibody binding with an excess of cognate pep-
tide.
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Figure 2 Relationship between level of ERBB3 mRNA expression and ERBB3 protein expression in human breast cell lines.
Upper panel shows Northern blot of RNA extracted from cell lines MTSV-1.7, ZR75-1 and BT483 hybridised with probes specific
for ERBB3 and beta actin. Lower panel shows cell pellets from these cell lines immunostained with antibody 49.3 against ERBB3
protein.
Statistical analysis
Relationships between variables were analysed using the Chi-
squared test. Survival curves were calculated using the
method of Kaplan & Meier (Peto et al., 1977) and differences
between curves were analysed by the logrank test.
Results
We observed a wide range in the level of expression of
ERBB3 mRNA and protein in the various breast cell lines
examined (Table I and Figure 2). The immortalised, non-
malignant cell lines, such as MTSV-1.7, showed barely detec-
table expression of ERBB3 at either mRNA or protein level.
On the other hand, ERRB3 expression was found in all of
the tumour-derived malignant cell lines. Some, such as the
ZR75 cell line, showed intermediate levels and some, such as
the BT483 cell line, showed very high expression. There was
good concordance between the intensity of signal on North-
ern blot analysis and the intensity of immunohistochemical
Table II Immunoreactivity for ERBB3 protein in breast cancer
Immunoreactivity scorea Number of cases
Less than normal 25
Normal range 128
More than normal 42
Total: 195
aStaining was assessed quantitatively according to the intensity of
the colour reaction and graded as less than normal, within the
normal range or more intense than normal. In general, staining was
fairly homogeneous within a particular tumour.
Table III Relationship between ERBB3 immunoreactivity and other
prognostic and biological variables
ERBB3 high
(score > 6)
Factor n = 42 P value
Tumour size:
<2cm 16/71 (23%) 094 >2cm 26/124 (21%)
Tumour gradea:
Grade 1 or 2 27/102 (26%) 0.29
Grade 3 12/66 (18%)
Nodal statusb:
Negative 15/103 (15%) 0.02
Positive 27/92 (29%)
1 -3 nodes pos. 16/60 (27%) 0.59
> 4 node pos. 11/32 (34%)
Steroid receptor statusc:
ER negative 11/46 (24%) 0.84
ER positive 29/138 (21%)
PgR negative 20/82 (24%) 0.57
PgR positive 20/101 (20%)
Growth factor receptor status:
EGFR negative 30/157 (19%)
EGFR positive 12/38 (32%) 0.14
ERBB2 negative 29/146 (20%)
ERBB2 positive 13/49 (27%) 0.43
p53 immunoreactivity:
Negative 36/157 (23%)
Positive 6/38 (16%) 0.46
aPathological grade of invasive ductal carcinomas. bNodal status
was not available in one case. CSteroid receptor status was not
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staining with the 49.3 antiserum (Figure 2). There was no
abnormality of structure or gene copy number observed on
Southern blot analysis of DNA from any of the cell lines.
In the normal breast tissue samples examined we found
that there was finely granular cytoplasmic immunoreactivity
of weak to moderate intensity in the luminal epithelial cells
of the ducts and acini throughout all phases of the menstrual
cycle, and in occasional cases there was also weak immuno-
reactivity in the myoepithelial cells.
In the 36 tumours analysed by Southern blot we detected
no abnormality of gene structure or copy number (data not
shown), but immunohistochemistry showed that there was
wide variation in the level of ERBB3 expression in the
primary breast cancer specimens. Immunohistochemistry with
the two anti-ERBB3 antibodies gave concordant results but
since the level of background staining of stromal tissues was
found to be less with 49.3 than with 61.3 in pilot studies on
36 cases, this antibody was used for the larger series of 195
cases (Table II). Twenty six (13%) of these 195 cases showed
no detectable immunoreactivity in tumour cells (i.e., less than
normal), while at the other end of the spectrum 42 cases
(22%) showed cytoplasmic staining of much greater intensity
than normal breast epithelium (Figure 3). The frequency of
high expression was higher in infiltrating ductal carcinomas
(39/168 cases, 23%) than in invasive lobular carcinomas
(3/24 cases, 12.5%), but this difference is not statistically
significant. We have seen only one case of breast cancer
displaying membrane staining with the anti-ERBB3 anti-
serum 49.3. In the remaining cases the level of immunoreac-
tivity in the tumour cells was similar to that observed in
normal breast epithelium.
There was a statistically significant association between
strong ERBB3 immunoreactivity (greater than normal breast
epithelium) and the presence of lymph node metastases
(P = 0.02, Table III). Those cases with overexpression of
ERBB3 showed no difference in survival compared to those
cases expressing normal or low levels, regardless of nodal
status (Figure 3). There was no association between the level
of expression of ERBB3 and tumour size or histological
grade ofinvasive ductal carcinomas (Table III). We found no
correlation between ERBB3 immunoreactivity and immuno-








Figure 3 Immunoreactivity for ERBB3 protein in a human
primary breast cancer. Primary antibody 49.3, immunoperoxidase
staining, counterstained with haematoxylin ( x 100).
Discussion
Our studies have shown that while the ERBB3 protein is
expressed in the majority of human breast cancers at levels
similar to those of the normal breast epithelium it is overex-
pressed in approximately 22% of cases. This overexpression
appears to be due to upregulation of ERBB3 gene transcrip-
tion rather than gene amplification.
Examination of the panel of breast cell lines showed that
there was close correlation between the level of ERBB3
mRNA expression and intensity of immunoreactivity with




Figure 4 Survival for patients with operable breast cancer according to tumour immunoreactivity with antibody 49.3.1120 N.R. LEMOINE et al.
very low levels of ERBB3 expression were detected in the
nonmalignant immortal cell lines, while higher levels were
found in the cell lines derived from tumours. None of these
cell lines showed amplification or rearrangement of the
ERBB3 gene, and nor did any of the primary breast cancers
which were examined by Southern blot.
Expression of ERBB3 showed a wide variation in the
tumour biopsies, some samples being completely negative by
immunohistochemistry while others were stained much more
strongly than normal breast epithelium. The immunoreac-
tivity was nearly always cytoplasmic and finely granular and,
in contrast to the usual patterns of ERBB2 and EGF recep-
tor overexpression in breast cancer, we saw only one case of
membrane staining for ERBB3. However, we have observed
more frequent membrane immunoreactivity for ERBB3 in
pancreatic cancers and gastric cancers (Lemoine et al., 1992).
Membrane immunoreactivity for the related receptor protein
ERBB2 is characteristically seen in tumour cases with very
high levels of expression associated with gene amplification
while cytoplasmic staining is usually indicative of lower levels
of expression (Venter et al., 1987). Our finding of cytoplas-
mic immunoreactivity may imply that the level of overexpres-
sion of the ERBB3 protein is relatively modest in breast
cancer. We found no evidence of ERBB3 gene amplification
in these tumours and cell lines, and similar findings were
reported in 17 breast cancer lines by Kraus et al. (1989).
However, the fact that immunoreactivity for this protein,
postulated to be a transmembrane receptor, is generally
confined to the cytoplasm is intriguing but not necessarily
surprising. There is evidence that substantial proportions of
EGFR and ERBB2 proteins may be in cellular pools other
than the plasma membrane, suggesting that cytoplasmic
immunoreactivity may be significant. Indeed, Kumar et al.
(1991) have recently shown that even in a cell line expressing
high levels of ERBB2 from multiple copies of the gene only
about 19% of the receptor protein was expressed on the cell
membrane, the remainder being in other cell fractions.
Overexpression of the ERBB3 protein in these breast
cancers was independent of the level of expression of either
the EGF receptor or the ERBB2 receptor. Both of the latter
have been reported to represent prognostic markers when
found overexpressed in breast cancer (reviewed in Gullick,
1990a), but in this present series ERBB3 overexpression was
not found to correlate with disease outcome. However, it was
associated with the presence of lymph node metastases. Our
previous experience with ERBB2 (Gullick et al., 1991b) sug-
gests that substantially larger series of cases will be required
to reliably confirm or exclude the utility of ERBB3 overex-
pression as a prognostic marker in breast cancer. Our report
shows that while high expression of this protein occurs in a
substantial proportion of breast cancers the majority of cases
show normal or low levels of expression. Whether ERBB3
represents an oncogene involved in breast cancer remains
uncertain.
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